ANEST IWATA (6381) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 Aug, 2025Executive summary
Net sales for Q1 FY2025 were 12,088 million yen, down 3.2% year-over-year, with declines in both revenue and profits.
Operating profit fell 8.7% to 929 million yen; ordinary profit dropped 22.8% to 1,315 million yen; profit attributable to owners of parent decreased 14.9% to 895 million yen.
Comprehensive income turned negative at -137 million yen, mainly due to foreign currency translation losses.
Air energy business saw lower sales and profits, mainly due to weak demand in China and reduced exports.
Coating business had lower sales but higher profits, with recovery in China offset by slower sales in Europe and Japan.
Financial highlights
Gross profit rose due to improved cost-to-sales ratio, but higher SG&A expenses and lower FX gains reduced overall profit.
Realized foreign exchange gains dropped by 338 million yen year-over-year.
Basic earnings per share for Q1 FY2025 was 22.77 yen, down from 26.52 yen in Q1 FY2024.
Total assets decreased to 67,135 million yen; equity ratio improved to 68.4%.
Dividend of 23 yen per share was paid for the period ended March 31, 2025.
Outlook and guidance
Full-year FY2025 guidance remains unchanged: net sales forecast at 58,000 million yen (+6.6% year-over-year), operating profit at 5,550 million yen (-6.0%), and profit attributable to owners of parent at 4,150 million yen (-3.0%).
Annual dividend forecast is 83 yen per share.
Revenue growth expected in Japan and overseas, but operating costs and labor expenses are anticipated to rise.
US trade policy impacts are being assessed but not yet reflected in forecasts.
Latest events from ANEST IWATA
- Profits and sales fell, but financial stability and full-year guidance were maintained.6381
Q3 202610 Feb 2026 - Sales and profit fell, but FX gains and cash flow stability kept guidance unchanged.6381
Q2 202628 Nov 2025 - Sales rose but profits fell on margin and forex pressures; outlook and dividend steady.6381
Q2 202413 Jun 2025 - Sales rose but profits fell on higher costs; full-year outlook maintained amid global risks.6381
Q1 202513 Jun 2025 - Sales up, profits down; FY2025 targets higher sales, lower earnings, and a dividend increase.6381
Q4 20256 Jun 2025 - Profit outlook cut as China lags and costs rise, but investment and R&D remain on track.6381
Q3 20255 Jun 2025